Investigating Neutrophil Extracellular Traps in Systemic Sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the role of Neutrophil Extracellular Traps (NETs) in patients with Systemic Sclerosis (SSC) and other connective tissue diseases. It will involve recruiting 100 SSC patients, 30 patients with other connective tissue diseases, and 130 healthy volunteers from the university hospital of Reims. Blood samples will be collected to analyze plasma, serum, and neutrophils to assess NET production and composition in relation to various complications and phenotypes of SSC. The study seeks to clarify the involvement of NETs in the pathogenesis of SSC and their potential correlation with disease manifestations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\*For patients of group 1:

* Patients with systemic sclerosis (ACR-EULAR Criteria)
* Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims
* Patients consenting to participate to the study
* Patients enrolled in the national healthcare insurance program

For patients of group 2:

* Patients with other connective tissue disease (ACR specific-disease criteria)
* Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims
* Patients consenting to participate to the study
* Patients enrolled in the national healthcare insurance program

For patients of group 3 (healthy volunteers)

* Patients eligible for blood donation (blood donation regulation criteria of January 11th 2022 decree)
* Patients without medical history of autoimmune systemic or chronic inflammatory systemic disease,
* Patients without current or past neoplasy disease,
* Patients without chronic metabolic pathology
* Patients without treatment by anti inflammatory or corticotherapy for the last 15 days,
* Patients without infectious pathology or inflammatory acute for the last 15 days
* Patients consenting to participate to the study

Exclusion Criteria for patients of all groups:

* Patients/Healthy volunteers under 18 years old
* Patients/Healthy volunteers protected by the law
* Patients/Healthy volunteers not consenting to participate to the study after information
* Patients with inflammatory pathology or infectious acute intercurrent pathology in the last 15 days before inclusion
* Pregnant or breastfeeding women

Where it's running

• Chu Reims
  Reims, France Recruiting

Study contacts

• Study coordinator: Kevin DIDIER, Dr.
• Email: kdidier@chu-reims.fr
• Phone: 03.26.83.24.44

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases

  This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07558850

• Imaging in Inflammatory Heart Diseases linked to autoimmune disorders

  This study tests how well multimodality imaging (CMR, echocardiography, and PET) detects inflammation in people with suspected inflammatory heart or autoimmune rheumatic diseases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07077304

• Using CAR-T cells to treat autoimmune diseases

  This study is testing a new treatment using modified T cells to see if it can help people with autoimmune diseases by targeting and removing harmful B cells.

  Recruiting Phase 1/2 Miltenyi Biomedicine GmbH · Erlangen, Bavaria · NCT06347718

• Registry and biorepository for rheumatic diseases

  This study is collecting samples and health information from adults with rheumatic diseases at Yale clinics to help researchers learn more about these conditions and improve future treatments.

  Recruiting Yale University · New Haven, Connecticut · NCT04402086

• Test of HBM7020 in healthy adults and adults with autoimmune diseases

  This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Brisbane, Queensland · NCT07649265

• Immun4Cure Cohort of Autoimmune Diseases

  A long-term, 500-person database and biobank is being built to study autoimmune diseases like RA, SLE, and scleroderma, plus healthy adults, using deep profiling and regular follow-ups over five years.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07515638

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.